Differences in Dry Eye Symptoms Related to Geographic Location in Spain and Impact of Artificial Tears Use
EMO-01
1 other identifier
observational
1,033
1 country
1
Brief Summary
This study assessed the differences in DED symptomatology measured with the OSDI questionnaire regarding climate data of the geographic location in a large population in Spain, with a special focus on the relative humidity (RH) of the place of residence and the impact of artificial tears use, to help eye care practitioners in patient management and education
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2022
CompletedFirst Submitted
Initial submission to the registry
July 5, 2024
CompletedFirst Posted
Study publicly available on registry
July 12, 2024
CompletedJuly 17, 2024
July 1, 2024
10 months
July 5, 2024
July 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
OSDI Score
Change in the Ocular Surface Disease Index (OSDI) score ranged from 0 (asymptomatic) to 100 (severe dry eye)
three months
Interventions
use of high molecular weight HA-based artificial tears three times per day
Eligibility Criteria
Health volunteers
You may qualify if:
- Volunteer subjects of legal age will be included who agree to participate in the study after being informed by the researcher of each center
You may not qualify if:
- Hyperthyroidis
- Rheumatism
- Lupus
- Autoimmune disease
- Previous diagnosis of Dye Eye Disease
- Cicatricial conjunctivitis
- Pterygium
- Eyelid trichiasis
- History of any eye medication use in the last 3 months to treat any eye condition (glaucoma, etc.)
- Active anterior eye inflammation (such as blepharitis, conjunctivitis, keratitis, scleritis, uveitis, etc.)
- Use of contact lenses in the last 3 months
- Previous ocular trauma or surgery in the last 6 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
IOBA Eye Institute
Valladolid, 47011, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Raul Martin, PhD
IOBA Eye Institute
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD
Study Record Dates
First Submitted
July 5, 2024
First Posted
July 12, 2024
Study Start
February 1, 2020
Primary Completion
November 30, 2020
Study Completion
January 31, 2022
Last Updated
July 17, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share
Data will be available by request to PI